IP Library › Granted Patent US 8,524,230
Granted Patent B2
US 8,524,230 · App. 12/643,152 · Granted Sep 3, 2013

Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,524,230
App. No.
12/643,152
Granted
Sep 3, 2013
Kind
B2
Abstract

Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.

Claims (1)

1. A method of treating an autoimmune-mediated ocular inflammatory disease (AOID) comprising administering to a subject in need of such treatment an antagonist of interleukin-23 (IL-23), wherein the AOID is chronic uveitis and the antagonist is a monoclonal antibody that specifically binds to the p19 subunit of IL-23.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →